Vaxcyte, Inc.
PCVX· Nasdaq
Released May 8, 2024, after the close
10-Q filed May 8, 2024, 38 days after period end · 0001628280-24-021677
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$95.02M | -$60.46M | -$38.99M | -$21.22M |
| EPS Diluted | -$0.85 | -$0.70 | -$0.68 | -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR